

India's Biocon Biologics to offer Oncology Biosimilars in over 30 countries

05 February 2021 | News

Inks agreement with the Clinton Health Access Initiative (CHAI) to expand access to cancer biosimilars through Cancer Access Partnership (CAP) in Africa and Asia



Biocon Biologics Ltd., a fully integrated 'pure-play' biosimilars company and a subsidiary of Biocon Ltd., has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).

Biocon Biologics' strong R&D and manufacturing capabilities have enabled the Company to offer affordable biologics such as bTrastuzumab and bPegfilgrastim to cancer patients in developed markets like the European Union (EU) and the United States (U.S.). Biocon Biologics aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quality, affordable biosimilar cancer therapies in 25 countries in Africa and 5 countries in Asia currently covered under CAP, led by CHAI. Biocon Biologics will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics said: "Biocon Biologics has been in the forefront of a long-running crusade against cancer through its high-quality affordable biosimilars. The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost-effective alternatives to expensive reference biologics. This is an extension of our commitment to enable universal access to cancer patients following the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs."

Biocon Biologics has developed monoclonal antibodies and therapeutic proteins for oncology, which are having a significant impact in the area of cancer care in several developed and emerging markets by providing high-quality, cost-effective alternatives to expensive reference biologics.

Biocon Biologics is the only Indian company to have commercialized three biosimilars – Trastuzumab, Pegfilgrastim and Insulin Glargine in the U.S. Its bTrastuzumab has received regulatory approvals in over 60 countries and has been commercialized in U.S., EU, Canada, Australia and selected Most of the World (MoW) markets. Its bPegfilgrastim has approvals in ~40 countries and is commercially available in U.S., EU, Canada and Australia currently.